Viewing Study NCT06543511



Ignite Creation Date: 2024-10-25 @ 8:05 PM
Last Modification Date: 2024-10-26 @ 3:37 PM
Study NCT ID: NCT06543511
Status: NOT_YET_RECRUITING
Last Update Posted: None
First Post: 2024-08-05

Brief Title: MyeloGen Germline Testing for Predisposition to Myeloid Malignancies
Sponsor: None
Organization: None

Study Overview

Official Title: MyeloGen Germline Testing for Predisposition to Myeloid Malignancies
Status: NOT_YET_RECRUITING
Status Verified Date: 2024-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This research study is evaluating the feasibility of conducting cancer genetic testing using healthy skin cells among participants with a diagnosis of a blood cancer Additionally investigators will evaluate how often participants with blood cancers are found to have risk for cancer based on family genes
Detailed Description: The purpose of this prospective non-randomized non-therapeutic single arm study is to determine the feasibility and benefit of performing genetic testing for all participants with a blood cancer diagnosis regardless of clinical suspicion

Research study procedures include screening for eligibility in-clinic visits questionnaires and skin punch biopsies Participants will receive germline genetic testing with a comprehensive hereditary cancer gene panel

It is expected that about 200 individuals with blood cancer will take part in this research study

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None